Superior vena cava syndrome is a common complication of malignancy. The epidemiology, presentation, and diagnostic evaluation of patients presenting with the syndrome are reviewed. Management options including chemotherapy and radiation…
Thrombosis is a common complication of cancer, occurring in up to 15% of patients. This article reviews the diagnosis and management of the most common cancer-related thrombotic problems; deep venous…
The bi-directional association between cancer and the coagulation system has been known for almost 2 centuries. During the past 2 decades research has focused on the precise mechanisms through which…
Direct oral factor IIa inhibitors represent a new class of anticoagulants for the prevention and treatment of venous and selected arterial thomboembolisms. Dabigatran etexilate is the most studied and promising…
Several new oral drugs that selectively and directly inhibit factor Xa seem promising alternatives to existing antithrombotic drugs. These drugs have a convenient route of administration, can be given in…
Although warfarin has been the mainstay of oral anticoagulation therapy for decades, evidence-based methods for improving the quality of warfarin therapy remain underused. The arrival of new anticoagulants that do…
Venous thromboembolic events are common in patients with malignancy, producing both morbidity and mortality. Although the underlying mechanisms by which cancer might promote a procoagulant state are multifaceted and incompletely…
VTE can be considered as a multicausal disease involving various inherited and acquired prothrombotic conditions. Although greater emphasis has classically been given to traditional thrombophilic risk factors, there is increasing…
Given the known increased risk of venous thromboembolism (VTE) associated with both oral contraceptive (OC) use and hormone replacement therapy (HRT), it is important to address questions about the prevention…
